Aromasin (Exemestane)
Brand Names: Aromasin
Methodology & AI Transparency ⓘ
Aromasin (Exemestane) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Aromasin (Exemestane) represents a prescription brand-name aromatase inhibitor entry registered by Pharmacia & Upjohn Company LLC with package codes 0009-7663.
- 2 Real-world patient consensus: Branded aromatase inhibitor presentation of Exemestane (Pharmacia & Upjohn Company LLC); generic reference: /meds/exemestane.
- 3 Typical cash cost range: Dispensing cost comparison spans $11.90 mail/discount cash up to $34.50 uninsured retail (federal NADAC $38.9792).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Aromasin (Exemestane) include headache (13%), fatigue (16%), insomnia (12%).
Ask our AI Specialists anything about Aromasin (Exemestane)
Aromasin (Exemestane) Mechanism, CYP450 Pathways & DailyMed Monograph
Aromasin (Exemestane) represents a prescription brand-name aromatase inhibitor entry registered by Pharmacia & Upjohn Company LLC with package codes 0009-7663. Reviewed against 2024-05-29 FDA SPL standards (25 mg/1 Tablet; 25mg Tablet), clinical deployment addresses Exemestane tablets are an aromatase inhibitor indicated for: adjuvant treatment of postmenopausal women with.
Aromasin achieves therapeutic action via Exemestane, engaging aromatase inhibitor physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 25 mg/1 Tablet; 25mg Tablet (registered by Pharmacia & Upjohn Company LLC, NDC 0009-7663), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Aromasin ($34.50 retail) with generic Exemestane ($11.90 low cash).
Pharmacokinetic profiling of Aromasin (Exemestane) demonstrates an elimination half-life of Mean elimination half-life of 4 to 13 hours across adult Aromasin (Exemestane) dosing with Oral fraction absorbed ranges from 45% to 57% (Aromasin (Exemestane) 25) systemic bioavailability; clearance proceeds via dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of aromasin (exemestane), reaching clinical onset within oral tmax achieved within 2 to 5 hours following aromasin (exemestane) ingestion.
Titration schedules for Aromasin (Exemestane) (25 mg/1 Tablet → 25mg Tablet) require excluding contraindicated in patients with prior serious allergic response to aromasin (exemestane) (ndc 0009-7663); severe baseline organ impairment where exemestane accumulation exceeds safe therapeutic margins; real-world patient logs highlight fatigue (16% of reports), headache (13% of reports), insomnia (12% of reports) alongside a 81.00% Worth-It consensus.
Rifampin or anticonvulsant inducers can diminish Aromasin (Exemestane) systemic exposure and clinical response.
Reconcile eGFR-adjusted medications before escalating Aromasin (Exemestane) in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Aromasin (Exemestane) (NDC 0009-7663)
- Severe baseline organ impairment where Exemestane accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (18 Reports)
Aromasin (Exemestane) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Aromasin (Exemestane))
Human clinical trial evidence for Aromasin (Exemestane) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Aromasin (Exemestane) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $38.9792/unit (~$1169.38/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $11.90 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $13.68 / mo | View logs ↓ |
Aromasin (Exemestane) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Aromasin (Exemestane) RxNorm Concept ID | 310261-B00097663 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $38.9792 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $11.90 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 81.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Aromasin (Exemestane) Patient Community, Cohort Filters & Dosage Logs
Deterministic Aromasin (Exemestane) reference combining NIH RxNorm (310261-B00097663), Medicaid NADAC ($38.9792/unit), and anonymous cohort outcomes (81% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Aromasin (Exemestane) community threads and patient logs by age, biological sex, dosage, and treatment duration.